The antidepressant agomelatine in daily practice: Results of the non-interventional study VIVALDI

Pharmacopsychiatry

Volumn 45, Issue 7, 2012, Pages 284-291

  Laux, G ^a  

^a Inn Salzach Klinikum   (Germany)

Author keywords

agomelatine; circadian rhythm; depression; non interventional study

Indexed keywords

AGOMELATINE; BENZODIAZEPINE; NEUROLEPTIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL PRACTICE; CONFUSION; DAYTIME SOMNOLENCE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DISSOCIATION; DIZZINESS; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; NAUSEA; NIGHTMARE; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; RATING SCALE; REMISSION; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL HALLUCINATION;

ACETAMIDES; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ANTIDEPRESSIVE AGENTS; ASPARTATE AMINOTRANSFERASES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PRIVATE PRACTICE; PSYCHIATRIC STATUS RATING SCALES; SLEEP DISORDERS, CIRCADIAN RHYTHM;

EID: 84869489079     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1309003     Document Type: Article

References (31)

1. Alonso J., Angermeyer M. C., Bernert S. et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl: 2004; 21 27
2. Kessler R. C., Berglund P., Demler O. et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA: 2003; 289 3095 3105
3. Sobocki P., Jonsson B., Angst J. et al. Cost of depression in Europe. J Ment Health Policy Econ: 2006; 9 87 98
4. Wehr T. A., Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria: 1982; 15 31 39
5. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol: 2006; 21 01 S11 S15
6. Nutt D., Wilson S., Paterson L. Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci: 2008; 10 329 336
7. Buysse D., Angst J., Gamma A. et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep: 2008; 31 473 480
8. Riemann D., Voderholzer U. Primary insomnia: a risk factor to develop depression. J Affect Disord: 2003; 76 255 259
9. Millan M. J., Gobert A., Lejeune F. et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther: 2003; 306 954 964
10. Masana M. I., Benloucif S., Dubocovich M. L. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J Pineal Res: 2000; 28 185 192
11. Neu J. M., Niles L. P. A marked diurnal rhythm of melatonin ML1A receptor mRNA expression in the suprachiasmatic nucleus. Brain Res Mol Brain Res: 1997; 49 303 306
12. Poirel V. J., Masson-Pevet M., Pevet P. et al. MT1 melatonin receptor mRNA expression exhibits a circadian variation in the rat suprachiasmatic nuclei. Brain Res: 2002; 946 64 71
13. Racagni G., Riva M. A., Molteni R. et al. Mode of action of agomelatine: synergy between melatonergic and 5-HT(2C) receptors. World J Biol Psychiatry: 2011; 12 574 587
14. Kasper S., Hajak G., Wulff K. et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry: 2010; 71 109 120
15. Olie J. P., Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol: 2007; 10 661 673
16. Kennedy S. H., Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol: 2006; 16 93 100
17. Kennedy S. H., Rizvi S., Fulton K. et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol: 2008; 28 329 333
18. Kasper S. Superior efficacy results of agomelatine in a pooled analysis versus SSRI SNRI. Eur Neuropsychopharmacol: 2010; 20 03 S348
19. Hale A., Corral R., Mencacci C. et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol: 2010; 25 305 314
20. Lemoine P., Guilleminault C., Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry: 2007; 68 1723 1732
21. Quera-Salva M. A., Hajak G., Philip P. et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol: 2011; 26 252 262
22. Kennedy S. H., Rizvi S. Agomelatine in the treatment of major depressive disorder review article. CNS Drugs: 2010; 24 479 499
23. Möller H. J., Schnitker J. Prospective study using a modified Montgomery-Asberg Depression Scale. Nervenarzt: 2007; 78 685 690
24. Laredo J., Quera Salva M. A., Falissard B. et al. Screening of sleep and circadian rhythms in major depression. J Sleep Res: 2002; 11 132 133
25. Loo H., Hale A., DHaenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol: 2002; 17 239 247
26. Goodwin G. M., Emsley R., Rembry S. et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry: 2009; 70 1128 1137
27. Goodwin G. M., Rouillon F., Emsley R. Long-term treatment with agomelatine:prevention of relapse in patients with major depressive disorder over 10 months. Eur Neuropsychopharmacol: 2008; 18 S338
28. Kim J. M., Kim S. Y., Stewart R. et al. Improvement within 2 weeks and later treatment outcomes in patients with depressive disorders: the CRESCEND study. J Affect Disord: 2011; 129 183 190
29. Montgomery S. A., Kennedy S. H., Burrows G. D. et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol: 2004; 19 271 280
30. Laux G., Studiengruppe V. Antidepressive Therapie mit Agomelatin in der Facharztpraxis. Ergebnisse der VIVALDI-Studie. Psychopharmakotherapie: 2011; 18 18 26
31. BfArM PE I. Gemeinsame Empfehlungen des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Planung. Durchführung und Auswertung von Anwendungsbeobachtungen (Entwurfsfassung vom 9. Mai 2007 zur Kommentierung durch die Fachöffentlichkeit): 2007